Preeclampsia Rapid Test

About Chembio Diagnostic Systems

Chembio Diagnostic Systems is a commercial-stage diagnostics company specializing in rapid point-of-care tests for infectious diseases. Its core innovation is the proprietary Dual Path Platform (DPP®) technology, which offers enhanced sensitivity and multiplexing capabilities compared to traditional lateral flow assays. The company has a diversified portfolio targeting HIV, syphilis, tropical diseases, respiratory illnesses (including COVID-19), and veterinary health, and is actively advancing its pipeline with support from grants and strategic designations like FDA Breakthrough Device status. Chembio operates as a subsidiary of the global diagnostics group Biosynex.

Therapeutic Areas

Other Preeclampsia Drugs